Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day
December 28 2020 - 9:15AM
Business Wire
Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene
regulatory and immunotherapeutic drugs utilizing spherical nucleic
acid (SNA™) technology, announced that it will host a virtual
R&D Day on Thursday, January 7th, 2021 from 09:00 am to 10:30
am ET to discuss Exicure’s neuroscience pipeline, including its
lead program for Friedreich’s Ataxia which has progressed into
IND-enabling studies.
Exicure’s Scientific Advisory Board member Dr. Susan Perlman and
the CEO of the Friedreich’s Ataxia Research Alliance (FARA)
Jennifer Farmer, will join Exicure’s leadership team in discussing
the company’s progress in Friedreich’s Ataxia and its expanding
neuroscience pipeline.
Susan L. Perlman, MD, is a Clinical Professor in the Department
of Neurology at the David Geffen School of Medicine at UCLA, where
she is also the Director of Clinical Trials and Director, Ataxia
Clinic for UCLA’s Neurogenetics program. She is a member of the
Medical Research Advisory Board for the National Ataxia Foundation
and has been a primary investigator for several Friedreich’s Ataxia
trials.
Jennifer Farmer, MS is the CEO of the Friedreich’s Ataxia
Research Alliance (FARA). Since joining FARA in 2006, she has led
FARA’s efforts to establish clinical research infrastructure and
clinical trial readiness, grown the research grant program, and led
efforts to engage bio-pharmaceutical companies in drug discovery
and development for Friedreich’s Ataxia.
A live webcast will be available in the Events and Presentations
section of Exicure’s website on January 7, 2021 at 09:00 am ET. An
archived version will be available on the company website following
the event. Additional information can be found here:
https://troutaccess.com/index.php/c/ExicureResearchDay2021
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company
developing therapeutics for neurology, immuno-oncology,
inflammatory diseases and other genetic disorders based on our
proprietary Spherical Nucleic Acid, or SNA technology. Exicure
believes that its proprietary SNA architecture has distinct
chemical and biological properties that may provide advantages over
other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure is in preclinical development of XCUR-FXN an
SNA–based therapeutic candidate, for the treatment of Friedreich’s
ataxia (FA). Exicure's drug candidate AST-008 is currently in a
Phase 1b/2 clinical trial in patients with advanced solid tumors.
Exicure is in Chicago, IL and has an office in Cambridge, MA.
For more information, visit Exicure’s website at
www.exicuretx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201228005178/en/
For Media: Karen Sharma MacDougall 781-235-3060
ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024